Exact Therapeutics AS (FRA:56F) WACC %:-0.95% (As of Jul. 21, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:56F Exact Therapeutics AS FRA:56F
21 GF Score
Price €0.03
! 2 Warning Signs
View Full Analysis

What is Exact Therapeutics AS WACC %?

Exact Therapeutics AS FRA:56F +2.00% 21 WACC % is -0.95% as of Jul. 21, 2026. GuruFocus rates FRA:56F with a GF Score™ of 21/100. The stock has 2 warning signs investors should review. Among 1,422 Biotechnology companies, Exact Therapeutics AS ranks better than 52.53% on this metric.

As of today (2026-07-21), Exact Therapeutics AS's weighted average cost of capital is -0.95%%. Exact Therapeutics AS's ROIC % is -235.38% (calculated using TTM income statement data). Exact Therapeutics AS earns returns that do not match up to its cost of capital. It will destroy value as it grows.

For a comprehensive WACC calculation, please access the WACC Calculator.


Exact Therapeutics AS  (FRA:56F) WACC % Explanation

Because it costs money to raise capital. A firm that generates higher ROIC % than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, Exact Therapeutics AS's weighted average cost of capital is -0.95%%. Exact Therapeutics AS's ROIC % is -235.38% (calculated using TTM income statement data). Exact Therapeutics AS earns returns that do not match up to its cost of capital. It will destroy value as it grows.


Be Aware

1. GuruFocus uses book value of debt (D) to do the calculation. It is simplified by adding latest one-year semi-annual average Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation together.
For companies that report quarterly, GuruFocus combines all of the most recent year's quarterly debt data from the beginning of the year to the year-end and calculates the average.
For companies that report semi-annually, GuruFocus combines all of the most recent year's semi-annual debt data from the start of the year to the year-end and calculates the average.
For companies that report annually, GuruFocus combines the beginning and ending annual debt data from the most recent year and then calculates the average.

2. The WACC formula discussed above does not include Preferred Stock. Please adjust if preferred stock is considered.

3. (Expected Return of the Market - Risk-Free Rate of Return) is also called market premium. GuruFocus requires market premium to be 6%.

4. GuruFocus uses the latest TTM Interest Expense divided by the latest one-year semi-annual average debt to get the simplified cost of debt.


Related Terms

Exact Therapeutics AS WACC % Historical Data

* Premium members only.

The historical data trend for Exact Therapeutics AS's WACC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Exact Therapeutics AS WACC % Chart

Exact Therapeutics AS Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
WACC %
Get a 7-Day Free Trial Premium Member Only 7.71 9.12 3.69 1.48 -2.06

Exact Therapeutics AS Semi-Annual Data
Dec17 Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
WACC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.69 3.38 1.48 4.61 -2.06

FRA:56F vs VRTX, REGN, ALNY: WACC % Comparison

For the Biotechnology subindustry, Exact Therapeutics AS's WACC %, along with its competitors' market caps and WACC % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Exact Therapeutics AS WACC % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Exact Therapeutics AS's WACC % distribution charts can be found below:

* The bar in red indicates where Exact Therapeutics AS's WACC % falls into.


FRA:56F
21GF Score
Exact Therapeutics AS FRA:56F
WACC % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Exact Therapeutics AS WACC % Calculation

The weighted average cost of capital (WACC) is the rate that a company is expected to pay on average to all its security holders to finance its assets. The WACC is commonly referred to as the firm's cost of capital. Generally speaking, a company's assets are financed by debt and equity. WACC is the average of the costs of these sources of financing, each of which is weighted by its respective use in the given situation. By taking a weighted average, we can see how much interest the company has to pay for every dollar it finances.

WACC=E/(E + D)*Cost of Equity+D/(E + D)*Cost of Debt*(1 - Tax Rate)

1. Weights:
Generally speaking, a company's assets are financed by debt and equity. We need to calculate the weight of equity and the weight of debt.
The market value of equity (E) is also called "Market Cap". As of today, Exact Therapeutics AS's market capitalization (E) is €7.136 Mil.
The market value of debt is typically difficult to calculate, therefore, GuruFocus uses book value of debt (D) to do the calculation. It is simplified by adding the latest one-year semi-annual average Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation together. As of Dec. 2025, Exact Therapeutics AS's latest one-year semi-annual average Book Value of Debt (D) is €0.041 Mil.
a) weight of equity = E / (E + D) = 7.136 / (7.136 + 0.041) = 0.9943
b) weight of debt = D / (E + D) = 0.041 / (7.136 + 0.041) = 0.0057

2. Cost of Equity:
GuruFocus uses Capital Asset Pricing Model (CAPM) to calculate the required rate of return. The formula is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)
a) GuruFocus uses 10-Year Treasury Constant Maturity Rate as the risk-free rate. It is updated daily. The current risk-free rate is 4.2027%. Please go to Economic Indicators page for more information. Please note that we use the 10-Year Treasury Constant Maturity Rate of the country/region where the company is headquartered. If the data for that country/region is not available, then we will use the 10-Year Treasury Constant Maturity Rate of the United States as default.
b) Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. Exact Therapeutics AS's beta is -0.8670.
c) (Expected Return of the Market - Risk-Free Rate of Return) is also called market premium. GuruFocus requires market premium to be 6%.
Cost of Equity = 4.2027% + -0.8670 * 6% = -0.9993%

3. Cost of Debt:
GuruFocus uses latest TTM Interest Expense divided by the latest one-year semi-annual average debt to get the simplified cost of debt.
As of Dec. 2025, Exact Therapeutics AS's interest expense (positive number) was €0.003 Mil. Its total Book Value of Debt (D) is €0.041 Mil.
Cost of Debt = 0.003 / 0.041 = 7.3171%.

4. Multiply by one minus TTM Tax Rate:
GuruFocus uses the most recent TTM Tax Expense divided by the most recent TTM Pre-Tax Income to calculate the tax rate. The calculated TTM tax rate is limited to between 0% and 100%. If the calculated tax rate is higher than 100%, it is set to 100%. If the calculated tax rate is less than 0%, it is set to 0%.
The latest calculated TTM Tax Rate = 0 / -7.435 = 0%.

Exact Therapeutics AS's Weighted Average Cost Of Capital (WACC) for Today is calculated as:

WACC=E / (E + D)*Cost of Equity+D / (E + D)*Cost of Debt*(1 - Tax Rate)
=0.9943*-0.9993%+0.0057*7.3171%*(1 - 0%)
=-0.95%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about WACC % →
What does a WACC % of -0.95% mean?
Exact Therapeutics AS (FRA:56F) has a WACC % of -0.95% as of Jul. 21, 2026. The weighted average cost of capital (WACC) is the average rate a company pays to finance assets. View historical data on Exact Therapeutics AS and its competitors. According to the industry distribution chart, Exact Therapeutics AS ranks #675 out of 1422 companies in the Biotechnology industry, placing it in the top 47.5%.
Is Exact Therapeutics AS's WACC % too high?
Exact Therapeutics AS's current WACC % is -0.95%. Based on the distribution chart, Exact Therapeutics AS ranks #675 out of 1422 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Exact Therapeutics AS has a GF Score™ of 21/100, reflecting its overall financial health beyond just this single metric.
How does Exact Therapeutics AS's WACC % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Exact Therapeutics AS ranks #675 out of 1422 companies for WACC %. This puts Exact Therapeutics AS in the upper half of its industry. The industry median WACC % is 10.02. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good WACC % for a Biotechnology company?
The median WACC % among Biotechnology companies is 10.02, based on 1,422 companies in the industry. Companies in the top quartile (top 25%) have a WACC % significantly above this median, while those in the bottom quartile fall well below. However, WACC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high WACC % mean?
A high WACC % can signal that a stock is expensive relative to its fundamentals. The weighted average cost of capital (WACC) is the average rate a company pays to finance assets. View historical data on Exact Therapeutics AS and its competitors. For the Biotechnology industry, the median WACC % is 10.02 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Exact Therapeutics AS's current WACC % is -0.95%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Exact Therapeutics AS stock overvalued right now?
Exact Therapeutics AS (FRA:56F) has a current WACC % of -0.95%. The current WACC % is -0.95%. Exact Therapeutics AS's overall GF Score™ is 21/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is WACC % calculated?
WACC % is calculated from a company's financial statements. For Exact Therapeutics AS (FRA:56F), the current WACC % is -0.95% as of Jul. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Exact Therapeutics AS Business Description

Other Exchanges EXTX:Norway
Address Ostre Aker Vei 19, Oslo, NOR, 0581
Exact Therapeutics AS is a clinical-stage biotechnology company focused on developing Acoustic Cluster Therapy (ACT), a non-invasive ultrasound-mediated technology for targeted enhancement of therapeutic agents. Its ACT platform (PS101) is being evaluated mainly in oncology, including pancreatic cancer and liver metastases, with additional applications in immuno-oncology, gene therapy, and central nervous system disorders.
21GF Score

Get the complete analysis for FRA:56F

WACC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.03
Price